Kincell integrates analytical strategy with process development to build robust, phase-appropriate methods that evolve from early CMC through commercial readiness. From cell therapy analytical development to qualification and GMP testing, our experts deliver identity, potency, and safety data you can trust, reducing risk, accelerating timelines, and supporting confident regulatory progression.
Cell therapy analytics are foundational to product consistency, safety, and regulatory success. Robust, phase-appropriate assays define identity, potency, purity, and stability while linking critical process parameters (CPPs) to clinical performance. Early investment in analytical strategy reduces comparability risk, strengthens regulatory filings, and builds the data foundation required for scalable, commercial-ready manufacturing.
Our analytical team views phase-appropriate analytics as a strategic, evolving framework.
Focus on fit-for-purpose release and potency assays optimized through Design of Experiments (DoE) to link CPPs to critical quality attributes (CQAs) and support IND readiness.
Analytical strategies must align with the distinct demands of autologous and allogeneic platforms, balancing variability, scalability, regulatory rigor, and long-term commercial performance.
Analytical approaches for autologous cell therapies must account for patient-to-patient variability while ensuring identity, potency, purity, and safety. Robust flow cytometry, functional potency assays, and molecular testing are combined with phase-appropriate controls to monitor consistency across individualized batches and protect the chain of identity.
Analytical approaches for allogeneic cell therapies emphasize batch consistency, scalability, and comparability. Robust potency assays, genetic modification testing, purity profiling, and in-process controls are used to monitor large-scale production. Advanced analytics and real-time data trending help ensure uniformity, regulatory compliance, and durable performance across broad patient populations.
Kincell Bio designs assay strategies that evolve with your program, from early feasibility through qualification and full validation. Using statistically driven optimization, we build robust, reproducible methods for identity, potency, purity, and safety. As data accumulates, specifications tighten, and methods transition from characterization to release testing, aligning with ICH guidances and preparing for pivotal studies, BLA submission, and commercial production.
Kincell Bio facilities are well-equipped with a range of platform technologies, enabling comprehensive analytical solutions that increase program success and derisk your development journey.
Kincell Bio develops and delivers tomorrow’s cell therapy cures by integrating comprehensive, end-to-end capabilities across the full product lifecycle, with deep expertise spanning a broad range of autologous and allogeneic cell therapy modalities.
Integrated Services
The Cornerstones of Cell Therapy Excellence, explores analytical, process development, quality, and manufacturing approaches that enable sustainable progress from early development through...
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
This webinar explores how integrated PD/AD expertise can deliver robust, regulatory-ready assays and accelerates cell therapy development.
Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields
